Clinical Trial Detail

NCT ID NCT00577278
Title Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

chronic lymphocytic leukemia

follicular lymphoma

non-Hodgkin lymphoma

lymphoplasmacytic lymphoma

Therapies

Ibritumomab tiuxetan

Methotrexate + Sirolimus + Tacrolimus

Rituximab

Fludarabine + Melphalan

Age Groups: adult

No variant requirements are available.